Herpes zoster‐associated voiding dysfunction in hematopoietic malignancy patients

Imafuku, Shinichi; Takahara, Masakazu; Uenotsuchi, Takeshi; Iwato, K.; Furue, Masutaka

doi:10.1111/j.1365-4632.2007.03548.x

Cited by 11 publications

(5 citation statements)

References 13 publications

(21 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HZ-induced neurogenic bladder can be induced by malfunction of detrusor reflex due to involvement of the sacral dorsal root ganglia, 6 VZV-induced meningitis and myelitis of the spinal cord. 7 While the average duration of skin rash by the onset of urinary symptoms was 6.5 days, the cases with severe skin lesions, such as ulceration, tended to present delayed occurrence of urinary symptoms as previously reported, 8 suggesting the requirement of continuous attention on urinary symptoms of sacral HZ patients.…”

Section: Discussionsupporting

confidence: 61%

Close correlation of herpes zoster‐induced voiding dysfunction with severity of zoster‐related pain: A single faculty retrospective study

Fujii

Takahashi

Honma

et al. 2015

The Journal of Dermatology

View full text Add to dashboard Cite

Herpes zoster (HZ), a common vesiculo-erythematous skin disease associated with reactivation of varicella zoster virus in the cranial nerve, dorsal root, and autonomic ganglia, is accompanied by several related symptoms represented by postherpetic neuralgia. Among them, involvement of vesicorectal dysfunction is relatively rare. The vesicorectal symptom can usually be recovered in transient course, but is quite important in terms of impaired quality of life. Male individuals affected with HZ and skin lesions on sacral dermatome have been reported as independent risk factors of zoster-related voiding dysfunction. In this study, urinary symptoms were focused upon and six patients with zoster-related voiding dysfunction at a single faculty of dermatology in Japan from 2009 to 2014 were retrospectively analyzed. All patients showed HZ lesions on the sacral area and the urinary symptom recovered in approximately 2 months (14 days to 7 months). The term of treatment for zoster-associated urinary dysfunction was positively correlated with that for zoster-related pain without significance (r = 0.661, P = 0.153). Average treatment term for pain relief of sacral HZ accompanied by voiding dysfunction (91.3 ± 76.44 days) was significantly longer than that of sacral HZ without urinary symptom (18.9 ± 20.42 days) (P = 0.032). These results suggested that zoster-related voiding dysfunction would mainly be involved in sacral HZ and closely associated with severity of zoster-related pain. Dermatologists should be aware that severe zoster-related pain accompanied by sacral HZ, which is related to prolonged treatment of pain relief, can be a predictive factor of voiding dysfunction.

show abstract

Section: Discussionsupporting

confidence: 61%

Close correlation of herpes zoster‐induced voiding dysfunction with severity of zoster‐related pain: A single faculty retrospective study

Fujii

Takahashi

Honma

et al. 2015

The Journal of Dermatology

View full text Add to dashboard Cite

show abstract

“…The severity of cutaneous symptoms was graded by dermatologists according to the proportion of affected area within the involved dermatome: mild, ≤30%; moderate, 30–70%; and severe, ≥70%. Pain severity was graded into four categories: negligible, mild, moderate, or severe.…”

Section: Methodsmentioning

confidence: 99%

One‐year follow‐up of zoster‐associated pain in 764 immunocompetent patients with acute herpes zoster treated with famciclovir (FAMILIAR study)

Imafuku

Nakayama

Higa

et al. 2014

Acad Dermatol Venereol

View full text Add to dashboard Cite

A total of 751 of 764 (98.3%) patients completed follow-up. The percentage of patients with ZAP was 12.4% at day 90, 7.1% at 6 months and 4.0% at 1 year. After the third month, the NRS were 3 or less in most of the remaining patients with ZAP. Stratified analysis revealed significant persistence of ZAP in patients aged ≥50 years and in those aged ≥65 years, and in patients with either moderate-to-severe skin symptoms or severe pain at the initial consultation.Stratified analyses unexpectedly showed patients who commenced famciclovir at 0-2 days after onset of the eruption had a higher prevalence of ZAP at day 90 than those treated at 3-5 days or ≥6 days after rash onset (P = 0.0164, log-rank test). On further analysis, a higher proportion of patients (45.4%) treated at 0-2 days had moderate to severe symptoms compared with those treated at 3-5 days (40.5%) or ≥6 days (37.0%) (P = 0.0987, Cochran-Armitage test). CONCLUSION & INFERENCE: This study, with an exceptionally high follow-up rate, revealed several new findings, including the influence of disease severity on the delay between the onset of symptoms and seeking medical attention. Six adverse drug reactions were reported in five of 721 patients in the safety analysis, including two severe cases of vomiting and convulsions.

show abstract

“…Voiding dysfunction associated with sacral HZ is uncommon but not rare, especially among immunocompromised patients [497]. The incidence among 423 Taiwanese HZ patients was 4% overall, and 29% among those with lumbosacral HZ [498].…”

Section: Complicating Presentations and Disease Associationsmentioning

confidence: 99%

Looking back to move forward: a twenty-year audit of herpes zoster in Asia-Pacific

et al. 2017

View full text Add to dashboard Cite

BackgroundHerpes zoster (HZ) is a prevalent viral disease that inflicts substantial morbidity and associated healthcare and socioeconomic burdens. Current treatments are not fully effective, especially among the most vulnerable patients. Although widely recommended, vaccination against HZ is not routine; barriers in Asia-Pacific include long-standing neglect of adult immunisation and sparse local data. To address knowledge gaps, raise awareness, and disseminate best practice, we reviewed recent data and guidelines on HZ from the Asia-Pacific region.MethodsWe searched PubMed, Scopus, and World Health Organization databases for articles about HZ published from 1994 to 2014 by authors from Australia, China, Hong Kong, India, Indonesia, Japan, Korea, Malaysia, New Zealand, the Philippines, Singapore, Taiwan, Thailand, and Vietnam. We selected articles about epidemiology, burden, complications, comorbidities, management, prevention, and recommendations/guidelines. Internet searches retrieved additional HZ immunisation guidelines.ResultsFrom 4007 retrieved articles, we screened-out 1501 duplicates and excluded 1264 extraneous articles, leaving 1242 unique articles. We found guidelines on adult immunisation from Australia, India, Indonesia, Malaysia, New Zealand, the Philippines, South Korea, and Thailand.HZ epidemiology in Asia-Pacific is similar to elsewhere; incidence rises with age and peaks at around 70 years – lifetime risk is approximately one-third. Average incidence of 3–10/1000 person-years is rising at around 5% per year. The principal risk factors are immunosenescence and immunosuppression. HZ almost always causes pain, and post-herpetic neuralgia is its most common complication. Half or more of hospitalised HZ patients have post-herpetic neuralgia, secondary infections, or inflammatory sequelae that are occasionally fatal. These disease burdens severely diminish patients’ quality of life and incur heavy healthcare utilisation.ConclusionsSeveral countries have abundant data on HZ, but others, especially in South-East Asia, very few. However, Asia-Pacific countries generally lack data on HZ vaccine safety, efficacy and cost-effectiveness. Physicians treating HZ and its complications in Asia-Pacific face familiar challenges but, with a vast aged population, Asia bears a unique and growing burden of disease. Given the strong rationale for prevention, most adult immunisation guidelines include HZ vaccine, yet it remains underused. We urge all stakeholders to give higher priority to adult immunisation in general and HZ in particular.Electronic supplementary materialThe online version of this article (doi:10.1186/s12879-017-2198-y) contains supplementary material, which is available to authorized users.

show abstract

Herpes zoster‐associated voiding dysfunction in hematopoietic malignancy patients

Abstract: In immune compromised subjects, attention should be paid to patients with herpes zoster in the lumbo-sacral area for late onset of acute urinary retention even after the resolution of skin symptoms.

Cited by 11 publications

References 13 publications

Close correlation of herpes zoster‐induced voiding dysfunction with severity of zoster‐related pain: A single faculty retrospective study

Close correlation of herpes zoster‐induced voiding dysfunction with severity of zoster‐related pain: A single faculty retrospective study

One‐year follow‐up of zoster‐associated pain in 764 immunocompetent patients with acute herpes zoster treated with famciclovir (FAMILIAR study)

Looking back to move forward: a twenty-year audit of herpes zoster in Asia-Pacific

Contact Info

Product

Resources

About